GlassScriptPhysician profile
Mark Randolph Jularbal
NPI 1720547771
$4,658.35
in general payments reported to CMS, 2019-2025
35 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,562 · 2022: $1,094 · 2023: $854 · 2024: $502 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $811.58 | 2021-2024 | Ztlido |
| Novartis Pharmaceuticals Corporation | $687.50 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $426.99 | 2021-2025 | Relistor |
| Amgen INC. | $389.92 | 2021-2025 | Uplizna |
| Collegium Pharmaceutical, INC. | $325.36 | 2021-2025 | Belbuca, Xtampza |
| Biohaven Pharmaceuticals, INC. | $225.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $223.16 | 2022 | |
| Abbvie INC. | $220.35 | 2021-2025 | |
| Nevro Corp. | $160.86 | 2023-2024 | Senza |
| Almatica Pharma LLC | $148.40 | 2021 | |
| Allergan, INC. | $129.31 | 2021 | |
| Forte Bio-Pharma LLC | $90.80 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Pfizer INC. | $87.03 | 2021-2025 | |
| Biogen, INC. | $71.43 | 2022-2024 | Vumerity |
| Abbott Laboratories | $56.51 | 2023-2025 | Proclaim, Penta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $53.65 | 2025 | |
| Adamas Pharmaceuticals, INC. | $50.72 | 2021 | |
| Lilly USA, LLC | $49.32 | 2022-2023 | Emgality, Reyvow |
| Upsher-Smith Laboratories LLC | $47.82 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $46.08 | 2021-2022 | |
| Ibsa Pharma INC. | $38.02 | 2022 | |
| Averitas Pharma INC. | $35.72 | 2025 | Qutenza |
| Biodelivery Sciences International, INC. | $32.88 | 2021 | |
| Supernus Pharmaceuticals, INC. | $28.32 | 2021 | |
| Lundbeck LLC | $25.66 | 2025 | Vyepti |
| Nestle Healthcare Nutrition INC. | $24.36 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.49 | 2022 | |
| Tg Therapeutics, INC. | $21.77 | 2025 | |
| Janssen Pharmaceuticals, INC | $21.20 | 2022 | |
| Inspire Medical Systems, INC. | $19.42 | 2023 | Inspire |
| Valinor Pharma, LLC | $19.16 | 2025 | Movantik |
| Redhill Biopharma INC. | $17.56 | 2021 | |
| Novo Nordisk INC | $16.98 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.71 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jularbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.